Guerbet SA (FRA:4G8)

Market Cap	123.63M -64.3%
Revenue (ttm)	798.67M -6.1%
Net Income	-108.33M
EPS	-8.59
Shares Out	n/a
PE Ratio	n/a
Forward PE	10.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	256
Open	9.12
Previous Close	8.45
Day's Range	9.12 - 9.12
52-Week Range	7.74 - 25.65
Beta	n/a
RSI	38.10
Earnings Date	Mar 11, 2026

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: X-Ray Apparatus and Tubes and Related Irradiation Apparatus
• Founded: 1926
• Employees: 2,842
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4G8